Ionis Pharmaceuticals (IONS)

Executive Summary

Ionis Pharmaceuticals is a fully integrated biotechnology company and a pioneer in RNA-targeted therapeutics, leveraging its antisense oligonucleotide platform to address serious genetic, cardiometabolic, and neurological diseases. Founded in 1989 and headquartered in Carlsbad, California, Ionis has multiple FDA-approved therapies generating commercial revenue, including Tegsedi (inotersen) and Spinraza (through a partnership with Biogen). The company operates a robust pipeline spanning early to late-stage programs, with a focus on rare diseases and conditions with high unmet need. Its proprietary antisense technology enables precise modulation of disease-causing proteins, positioning Ionis as a leader in precision medicine. With over 35 years of innovation and a strong intellectual property estate, the company continues to expand its reach through internal development and strategic collaborations. Looking ahead, Ionis has several near-term catalysts that could drive significant value. The most advanced late-stage program is donidalorsen, a Phase 3 antisense therapy for hereditary angioedema (HAE), with top-line data expected in late 2026. Positive results could support a New Drug Application filing, offering a new treatment option for HAE patients. Additionally, the company is progressing ION582 in Angelman syndrome (Phase 1/2) and ION464 in multiple system atrophy (Phase 1), with initial data readouts anticipated in 2027. These programs highlight Ionis's expertise in neurology and its ability to target the root cause of devastating genetic disorders. With a strong balance sheet and a track record of regulatory success, Ionis is well-positioned to deliver transformative therapies and generate long-term shareholder value.

Upcoming Catalysts (preview)

• Q4 2026Donidalorsen Phase 3 top-line data for hereditary angioedema75% success
• 2027ION582 Phase 1/2 interim data for Angelman syndrome50% success
• 2027ION464 Phase 1 initial data for multiple system atrophy40% success